Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 1.4% – Should You Sell?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares fell 1.4% during trading on Wednesday . The stock traded as low as $0.2250 and last traded at $0.2251. 209,065 shares traded hands during trading, a decline of 67% from the average session volume of 633,613 shares. The stock had previously closed at $0.2284.

Theriva Biologics Trading Down 1.4%

The company’s 50 day simple moving average is $0.25 and its two-hundred day simple moving average is $0.24. The company has a market capitalization of $7.59 million, a price-to-earnings ratio of -0.01 and a beta of 1.11. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.30 million for the quarter.

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently raised its position in Theriva Biologics stock. Geode Capital Management LLC grew its holdings in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the period. Geode Capital Management LLC owned 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities & Exchange Commission. 6.17% of the stock is currently owned by institutional investors and hedge funds.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.